What are the current headline metrics for SUNPHARMA?

Sun Pharmaceutical Industries Limited is currently shown with a delayed price near ₹1,777.7, P/E 38.9.

Does the SUNPHARMA page provide investment advice?

No. The SUNPHARMA page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Stocks›Healthcare

Watch Alert

Sun Pharmaceutical Industries Limited

SUNPHARMA · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,777.70

+₹16.70 (+0.95%)(1D)

₹1,583.7052 Week Range₹2,046.90

Anvest Score

63/100

Valuation

34/100

Quality

65/100

Growth

69/100

Health

99/100

Momentum

54/100

Valuation
34
Quality
65
Growth
69
Health
99
Momentum
54

Loading company profile…

More Page Context

Research at a glance

Sun Pharmaceutical Industries Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,777.7

Market cap

₹4,26,786 Cr

P/E ratio

38.9

P/B ratio

5.11

Dividend yield

Not available

ROE

Not available

RSI 14

47.71

1Y return

Not available

Sun Pharmaceutical Industries Limited FAQs

3 topics

Expand

Stocks›Healthcare

Watch Alert

Sun Pharmaceutical Industries Limited

SUNPHARMA · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,777.70

+₹16.70 (+0.95%)(1D)

₹1,583.7052 Week Range₹2,046.90

Anvest Score

63/100

Valuation

34/100

Quality

65/100

Growth

69/100

Health

99/100

Momentum

54/100

Valuation
34
Quality
65
Growth
69
Health
99
Momentum
54

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Sun Pharmaceutical Industries Limited is a leading Indian multinational pharmaceutical company that develops, manufactures, and markets a wide range of branded and generic formulations, active pharmaceutical ingredients (APIs), and specialty products. It operates globally, with a strong presence in India and the US, and is a major player in the specialty and generic drug manufacturing sector.

Drug Manufacturers - Specialty & GenericGlobal FootprintFounded:1983CEO/MD:Dilip ShanghviHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

It has a robust manufacturing footprint globally, supporting its diverse product portfolio.
Sun Pharma generates revenue by researching, developing, manufacturing, and selling a diverse portfolio of pharmaceutical products, including branded generics, specialty products, over-the-counter (OTC) drugs, and APIs.
Additionally, Sun Pharma is expanding its product portfolio through strategic acquisitions, such as the planned acquisition of Innovcare Lifesciences Private Limited, which is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products.

Revenue growth: +11.2%FY26 growth+10.0%3Y CAGR
EPS growth: +4.8%FY26 growth+10.6%3Y CAGR
CFO / PAT: 1.08×FY26

What Looks Strong

GrowthRevenue grew at +10.0% CAGR over three years.
Cash FlowOperating cash flow was 1.08× total net profit in FY26.
MarketShareholder returns of +18.1% CAGR over five years.

What to Watch

No material watchpoint identified from currently verified evidence.

Reports a single operating segment in its results filings.
They leverage their R&D capabilities and manufacturing infrastructure to serve both regulated and emerging markets worldwide.
The company operates across various therapeutic areas, including psychiatry, neurology, cardiology, orthopedics, diabetology, and gastroenterology.

FY26 (consolidated): revenue ₹58,462 cr, up 11% from ₹52,578 cr in FY25; net profit ₹11,479 cr, up 5% from ₹10,965 cr in FY25.
FY26 (consolidated): operating cash flow ₹12,419 cr (1.1× net profit); debt/equity 0.05×.
Latest quarter to Sep 2026 (consolidated): revenue ₹16,199 cr (up 12% year on year); net profit ₹1,995 cr.

Loading company profile…

More Page Context

Research at a glance

Sun Pharmaceutical Industries Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,777.7

Market cap

₹4,26,786 Cr

P/E ratio

38.9

P/B ratio

5.11

Dividend yield

Not available

ROE

Not available

RSI 14

47.71

1Y return

Not available

Sun Pharmaceutical Industries Limited FAQs

3 topics

Expand

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Sun Pharmaceutical Industries Limited is a leading Indian multinational pharmaceutical company that develops, manufactures, and markets a wide range of branded and generic formulations, active pharmaceutical ingredients (APIs), and specialty products. It operates globally, with a strong presence in India and the US, and is a major player in the specialty and generic drug manufacturing sector.

Drug Manufacturers - Specialty & GenericGlobal FootprintFounded:1983CEO/MD:Dilip ShanghviHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

It has a robust manufacturing footprint globally, supporting its diverse product portfolio.
Sun Pharma generates revenue by researching, developing, manufacturing, and selling a diverse portfolio of pharmaceutical products, including branded generics, specialty products, over-the-counter (OTC) drugs, and APIs.
Additionally, Sun Pharma is expanding its product portfolio through strategic acquisitions, such as the planned acquisition of Innovcare Lifesciences Private Limited, which is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products.

Revenue growth: +11.2%FY26 growth+10.0%3Y CAGR
EPS growth: +4.8%FY26 growth+10.6%3Y CAGR
CFO / PAT: 1.08×FY26

What Looks Strong

GrowthRevenue grew at +10.0% CAGR over three years.
Cash FlowOperating cash flow was 1.08× total net profit in FY26.
MarketShareholder returns of +18.1% CAGR over five years.

What to Watch

No material watchpoint identified from currently verified evidence.

Reports a single operating segment in its results filings.
They leverage their R&D capabilities and manufacturing infrastructure to serve both regulated and emerging markets worldwide.
The company operates across various therapeutic areas, including psychiatry, neurology, cardiology, orthopedics, diabetology, and gastroenterology.

FY26 (consolidated): revenue ₹58,462 cr, up 11% from ₹52,578 cr in FY25; net profit ₹11,479 cr, up 5% from ₹10,965 cr in FY25.
FY26 (consolidated): operating cash flow ₹12,419 cr (1.1× net profit); debt/equity 0.05×.
Latest quarter to Sep 2026 (consolidated): revenue ₹16,199 cr (up 12% year on year); net profit ₹1,995 cr.

Sun Pharmaceutical Industries Limited

Research at a glance

Sun Pharmaceutical Industries Limited FAQs

Sun Pharmaceutical Industries Limited

Business at a Glance

What Looks Strong

What to Watch

Research at a glance

Sun Pharmaceutical Industries Limited FAQs

Related paths

Related insights

DIVISLAB

TORNTPHARM

LAURUSLABS

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Business at a Glance

What Looks Strong

What to Watch